Known targets — ChEMBL curated mechanism
AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA
The experimentally established mechanism targets of Methacrylic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.48 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.39 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | CA4 | P22748 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Styrene SCHEMBL1728767 | 0.88 | ALDH1A1 (0.54) | ALDH1A1TDP1TSHRHDAC8CYP3A4 | |
| Styrene SCHEMBL2711946 | 0.88 | ALDH1A1 (0.54) | ALDH1A1TDP1TSHRHDAC8CYP3A4 | |
| Styrene SCHEMBL7950784 | 0.86 | ALDH1A1 (0.52) | ALDH1A1TDP1TSHRHDAC8CYP3A4 | |
| Methacrylic Acid SCHEMBL28243618 | 0.86 | TDP1 (0.70) | ALDH1A1TDP1TAS1R3TAS1R1TSHR | |
| Methacrylic Acid SCHEMBL2116687 | 0.86 | TDP1 (0.50) | ALDH1A1TDP1TAS1R3TAS1R1 | |
| Methacrylic Acid SCHEMBL1900788 | 0.84 | ALDH1A1 (0.52) | ALDH1A1TDP1TAS1R3TAS1R1TSHR | |
| Methacrylic Acid SCHEMBL14941456 | 0.83 | HDAC8 (0.62) | ALDH1A1TDP1TSHRHDAC8CYP2C19 | |
| SCHEMBL28247211 | 0.82 | TDP1 (0.55) | ALDH1A1TDP1TAS1R3TAS1R1TSHR | |
| Methacrylic Acid SCHEMBL27602455 | 0.82 | ALDH1A1 (0.50) | ALDH1A1TDP1TAS1R3TAS1R1TSHR | |
| Methacrylic Acid SCHEMBL460575 | 0.78 | ALDH1A1 (0.40) | ALDH1A1TDP1CYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9149439-B2 | Multi-particulate, modified-release composition | SANDOZ AG (CH) | 2015-10-06 | — | — | US | claimed |
| US-20090060848-A1 | PHARMACEUTICAL COMPOSITION WHICH REDUCES OR ELIMINATES DRUG ABUSE POTENTIAL | JOSHI YATINDRA | 2009-03-05 | — | — | US | claimed |
| EP-1954282-A2 | NOVEL PROCESS AND FORMULATIONS | GLAXO GROUP LIMITED (GB) | 2008-08-13 | — | — | EP | claimed |
| US-20070148247-A1 | Pharmaceutical composition which reduces or eliminates drug abuse potential | JOSHI YATINDRA | 2007-06-28 | — | — | US | claimed |
| WO-2007059500-A2 | NOVEL PROCESS AND FORMULATIONS | GLAXO GROUP LIMITED (GB) | 2007-05-24 | — | — | WO | claimed |
| US-20070048379-A1 | Valproate tablet | GUO MINTONG | 2007-03-01 | — | — | US | claimed |
| WO-2006102446-A2 | MULTI-PARTICULATE, MODIFIED-RELEASED COLONIC COMPOSITION | SANDOZ AG (CH) | 2006-09-28 | — | — | WO | claimed |
| US-20060210631-A1 | Multi-particulate, modified-release composition | SANDOZ AG (CH) | 2006-09-21 | — | — | US | claimed |
| WO-2005077342-A1 | ENTERICALLY COATED LANSOPRAZOLE MICROTABLETS | SANDOZ AG (CH) | 2005-08-25 | — | — | WO | claimed |
| US-20050181052-A1 | Lansoprazole microtablets | PATEL SATISHKUMAR A (US) | 2005-08-18 | — | — | US | claimed |
| US-20040042964-A1 | Pharmaceutical composition which reduces or eliminates drug abuse potential | JOSHI YATINDRA (US) | 2004-03-04 | — | — | US | claimed |
| US-20020187192-A1 | Pharmaceutical composition which reduces or eliminates drug abuse potential | JOSHI YATINDRA (US) | 2002-12-12 | — | — | US | claimed |
| WO-2002087558-A1 | PHARMACEUTICAL COMPOSITION WHICH REDUCES OR ELIMINATES DRUG ABUSE POTENTIAL | NOVARTIS AG (CH) | 2002-11-07 | — | — | WO | claimed |
| US-12042481-B2 | Use of (1R,5S)-(+)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane in the treatment of conditions affected by monoamine neurotransmitters | OTSUKA AMERICA PHARMACEUTICAL, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-20240100023-A1 | Compositions and Methods For Treating Spinal Cord Injuries | LIPPA ARNOLD S (US) | 2024-03-28 | — | — | US | disclosed |
| US-20230373982-A1 | Compositions And Methods For Treating Attention Deficit Disorders | LIPPA ARNOLD STAN (US) | 2023-11-23 | — | — | US | disclosed |
| EP-1025841-A1 | Bilayered amoxycillin tablets | SMITHKLINE BEECHAM PLC (GB) | 2000-08-09 | — | — | EP | disclosed |
| EP-0742712-A1 | BILAYERED AMOXYCILLIN TABLETS | SMITHKLINE BEECHAM PLC (GB) | 1996-11-20 | — | — | EP | disclosed |
| US-5464633-A | Core containing active substance to be released in gastric or intestinal tract, polymer which swells and/or gels and/or erodes on contact with water, and adjuvants and excipients; layer applied to core by compression process | JAGOTEC AG (CH) | 1995-11-07 | — | — | US | disclosed |
| WO-1995020946-A1 | BILAYERED AMOXYCILLIN TABLETS | SMITHKLINE BEECHAM PLC (GB) | 1995-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240100023-A1 | Compositions and Methods For Treating Spinal Cord Injuries | CHAT, NTRK2, GMFG | ALDH1A1 581/4885TDP1 943/4885TAS1R3 4607/4885 |
| US-12042481-B2 | Use of (1R,5S)-(+)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane in the treatment of conditions affected by monoamine neurotransmitters | HTR5A, CHRNA5, HTR1A | ALDH1A1 90/4885TDP1 406/4885TAS1R3 3310/4885 |
| US-20230373982-A1 | Compositions And Methods For Treating Attention Deficit Disorders | GRIN2A, GRIN2C, GRM2 | ALDH1A1 1104/4885TDP1 993/4885TAS1R3 4030/4885 |
| US-20070048379-A1 | Valproate tablet | CACNA1A, SUCLG2, CACNA1G | ALDH1A1 1386/4885TDP1 1589/4885TAS1R3 4047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.